GlobalData on MSN5d
FDA approves MSD’s KEYTRUDA as first-line MPM treatment
The approval for the KEYTRUDA regimen is supported by results from the Phase II/III IND.227/KEYNOTE-483 trial.
ThePrint on MSN4d
This experimental lung cancer drug outperforms blockbuster medicine Keytruda. But there’s a catch
In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...
A Better Drug Than Merck’s Blockbuster Keytruda? Not So Fast
Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year.
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
FierceBiotech10d
ESMO: IO Biotech's vaccine and Keytruda combo hits primary endpoint in phase 2 squamous cell carcinoma trial
Immune checkpoint inhibitors are the superheroes of cancer therapy. | Immune checkpoint inhibitors are the superheroes of ...
Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522
In 2021, the FDA criticised MSD for relying on an early endpoint to seek approval for Keytruda in early-stage TNBC.
Merck Stock Falls After Rival Summit Beats Keytruda Cancer Drug in Trial
Merck stock was falling. Rival Summit Therapeutics said its cancer drug Ivonescimab reduced the risk of disease progression ...
Keytruda beaten by Summit’s bispecific in NSCLC
The China-based trial enrolled 398 patients who were randomised to the ivonescimab and Keytruda arms at a one-to-one ratio.
10 Best Health Care Stocks to Buy for 2024
Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...
Summit shares hit record high as cancer drug tops Keytruda in China trial
Summit Therapeutics shares surged 37% in premarket trading on Monday after a study in China showed some lung cancer patients on the company's experimental drug had better survival rates than those on ...
3 No-Brainer Dividend Stocks to Buy in September
Three Fool.com contributors were asked to recommend some no-brainer dividend stocks to buy in September. They selected healthcare companies AbbVie (NYSE: ABBV), Merck (NYSE: MRK), and Pfizer (NYSE: ...
The Sanford Herald6d
Post-Op Keytruda Boosts Bladder Cancer Outcomes
When bladder cancer invades nearby muscle, total removal of the organ is the standard of care A new trial finds that post-op ...